
Lumentum CEO Defends Proposed Marvell Deal After Investor Backlash as Stock Trails 4.5 Marvell Shares by 14.1%
Hurlston defends the proposed Marvell deal after investor backlash, but Lumentum closed on 19 November 2026 at a 14.1% discount to the value of 4.5 Marvell shares. We expect the discount to stay at or above 11.3% on 2 December 2026.
At the 19 November 2026 close, Lumentum investors could buy a promise of $623.12 in Marvell stock for $535.15. The stock itself is due only if the proposed acquisition closes, which the companies expect in the first half of 2028. Under the agreement announced on 2 November 2026, Marvell will exchange 4.500 of its shares for every Lumentum share. Marvell closed at $138.47, making the package worth 4.5 times $138.47, or $623.12. Against Lumentum's $535.15 close, 1 minus $535.15 divided by $623.12 leaves a 14.1% discount for uncertain delivery.
Lumentum chief executive Michael Hurlston defended Marvell's proposed acquisition in a 19 November 2026 interview, after investors punished both stocks. We would pass on Lumentum as a rapid merger spread trade: we expect its discount to 4.5 times Marvell's close to remain at or above 11.3% on 2 December 2026. The Closing Toll is the markdown investors charge for waiting through shareholder votes and regulatory reviews before fixed ratio shares arrive. Hurlston's operating argument can lift the value of the shares. Closing the transaction requires a different kind of persuasion.
The $115 billion in the announcement was implied enterprise value at signing, rather than a guaranteed payment; the companies then valued the consideration at roughly $1,132 per Lumentum share. From the unaffected 28 October 2026 close to 19 November 2026, Marvell fell from $251.65 to $138.47, or 45.0%, and Lumentum from $913.95 to $535.15, or 41.4%. From the 2 November 2026 announcement close, Marvell's $171.41 became $138.47, down 19.2%, while Lumentum's $684.40 became $535.15, down 21.8%. The fixed ratio transmitted much of Marvell's decline directly into Lumentum's promised consideration, while Lumentum also traded below that consideration.
The exposure is more tangible in a scenario, rather than a forecast. Lumentum had 90.7 million shares outstanding on 30 October 2026. Hold that count constant at the 19 November 2026 closes: $535.15 times 90.7 million is about $48.5 billion of market value, while $623.12 times the same count is about $56.5 billion of implied consideration. That leaves roughly $8.0 billion between the stock market's price and the deal's conditional value. Buying Lumentum to collect that difference means accepting the conditions attached to it.
Hurlston can point to exceptional growth. Lumentum's quarter ended 26 September 2026 generated $1,262.6 million in revenue versus $533.8 million a year earlier, a 136.5% gain, and $644.0 million of gross profit. Marvell's quarter ended 1 August 2026 produced revenue of $2,739.3 million versus $2,006.1 million, about 37% higher. Management expects more than $1 billion in annual run rate cost synergies and accretion to Marvell's non-GAAP earnings per share in the first year after closing. That growth makes Hurlston's defense credible without fixing the exchange discount.
Marvell kept the $3.150 billion revenue guidance midpoint for its fiscal third quarter of 2027 when the deal was announced, narrowing the range from plus or minus 5% to 2%. Its results call is scheduled for 1 December 2026 at 1:30 p.m. Pacific, after the U.S. market closes. A stronger Marvell price would make 4.5 Marvell shares worth more dollars to a Lumentum holder. A narrower discount would say something else: investors have increased what they will pay today for the same conditional promise.
Hurlston's best counterargument begins with ownership, rather than operations. In Semafor on 19 November 2026, he put shareholder overlap at 80% and described forced selling by managers limited to holding one name. A combination can force a portfolio to sell shares it otherwise wants. The resulting pressure can disappear as those mandates are satisfied, without a shareholder vote or regulatory clearance. On CNBC, Hurlston said, "I think we're going to get that multiple back once we can show our numbers and show how strong the two businesses are doing." Marvell's results, the Form S-4 and Lumentum's own earnings offer a path to a smaller gap before the deal closes.
From 2 November 2026 through 19 November 2026, every Lumentum close was between 11.3% and 16.5% below 4.5 times Marvell's closing price. The last discount, 14.1%, persisted alongside Lumentum's latest 136.5% revenue growth. Ownership turnover could still unwind quickly after Marvell's results. Yet the same short trading period already includes a market that repeatedly valued the contingent consideration below its contractual ratio. We expect at least an 11.3% Closing Toll on 2 December while the votes and regulatory reviews remain ahead.
The same pair traded much closer before the agreement. On 29 October 2026, Lumentum's $919.53 close against Marvell's $218.34 meant a 6.4% discount to the eventual ratio. On 30 October 2026, the respective prices of $840.70 and $196.40 cut that to 4.9%. Those rumor prices preceded binding terms, votes and a timetable. At the 2 November 2026 announcement close, Lumentum's $684.40 against Marvell's $171.41 meant an 11.3% discount, rising to 14.1% by 19 November 2026. Signing gave the market terms and a longer list of ways delivery can fail.
Reuters valued the equity transaction at $102.5 billion on 2 November 2026, more than ten times Marvell's $10 billion Inphi acquisition in 2021. Its calculation put Lumentum at about 33 times projected core operating profit for the next year against a peer median around 16 times. Axel Rudolph of IG Group called it "an enormous bet" and questioned the price. At 4.5 new shares for each of Lumentum's 90.7 million outstanding, Marvell would issue about 408 million shares. Approval has real consequences for the buyer's existing holders.
The 2 November 2026 merger filing requires Lumentum holders to adopt the agreement and Marvell holders to approve the issuance and a charter amendment. There are U.S. antitrust requirements and other approvals. The companies expect to close in the first half of 2028; an outside date of 1 November 2027 can extend to 1 August 2028 for regulatory delays. Specified endings trigger Marvell fees of $5.8 billion or $3.2 billion for regulatory termination, or a $2.9 billion Lumentum fee. The penalties raise the cost of walking away but leave shareholders waiting for stock.
Revenue growth of 136.5% strengthens the standalone case, giving holders another reason to scrutinize a fixed exchange into Marvell. Hurlston acknowledged in Semafor that investors felt they had surrendered upside for a company whose prospects seemed less familiar. Better results at Marvell can change their minds, but even that success leaves the 4.500 share ratio unchanged. The rally he wants is easier to earn than a completed acquisition.
We would pass on Lumentum as a rapid convergence trade while the Closing Toll covers two votes and a timetable stretching into 2028. We would be wrong if the Nasdaq closing prices for Lumentum and Marvell on 2 December 2026 put the discount, calculated as 1 minus Lumentum's close divided by 4.5 times Marvell's close, below 11.3%.